Deals
Teva CEO: $40.5 Billion Deal Is Just the Beginning
Teva Purchasing Allergan's Generics Unit in $40.5B Deal
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd.’s chief executive officer doesn’t see his $40.5 billion deal to acquire Allergan Plc’s generic unit as the end of the company’s deal-making.
“The industry has been undergoing a huge change that’s maybe the most profound disruption that the pharma industry has been witnessing,” CEO Erez Vigodman said in an interview Monday. “You cannot sit still.”